Swiss pharmaceutical company Novartis AG is to invest $100 million in building a biomedical research and development center in Shanghai, China. Research and development activities at the site will initially focus on addressing urgent medical needs in China and Asia, particularly infectious causes of cancer endemic to the region, Novartis said. “The level of scientific expertise in China is rising rapidly. At the same time, the healthcare needs of the Chinese are growing, primarily the result of urbanization, lifestyle changes and associated chronic diseases,” said Dr Daniel Vasella, chairman and CEO of Novartis.
